Search Results - "Munster, P N"

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer by Munster, P N, Thurn, K T, Thomas, S, Raha, P, Lacevic, M, Miller, A, Melisko, M, Ismail-Khan, R, Rugo, H, Moasser, M, Minton, S E

“…Background: Histone deacetylases (HDACs) are crucial components of the oestrogen receptor (ER) transcriptional complex. Preclinically, HDAC inhibitors can…”
Get full text

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy by Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P.N., Chmielowska, E., Fumoleau, P., Ward, R., Bardy-Bouxin, N., Leip, E., Turnbull, K., Zacharchuk, C., Epstein, R.J.

“…This phase II study evaluated single-agent bosutinib in pretreated patients with locally advanced or metastatic breast cancer. Patients received oral bosutinib…”
Get full text

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates by Kelley, R.K., Nimeiri, H.S., Munster, P.N., Vergo, M.T., Huang, Y., Li, C.-M., Hwang, J., Mulcahy, M.F., Yeh, B.M., Kuhn, P., Luttgen, M.S., Grabowsky, J.A., Stucky-Marshall, L., Korn, W.M., Ko, A.H., Bergsland, E.K., Benson, A.B., Venook, A.P.

“…Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety,…”
Get full text

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma by Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I

“…Background: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I…”
Get full text

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours by Piha-Paul, S.A, Munster, P.N, Hollebecque, A, Argilés, G, Dajani, O, Cheng, J.D, Wang, R, Swift, A, Tosolini, A, Gupta, S

“…Abstract Background The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K-AKT-mTOR) signalling pathway is aberrantly activated…”
Get full text

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker by Munster, P N, Marchion, D, Thomas, S, Egorin, M, Minton, S, Springett, G, Lee, J-H, Simon, G, Chiappori, A, Sullivan, D, Daud, A

“…Background: Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA…”
Get full text

Maintenance lenalidomide in primary CNS lymphoma by Rubenstein, J.L., Geng, H., Vu, K., Mannis, G., Formaker, P., Hwang, J., Munster, P.N., Damato, B.

Get full text

Randomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab by Munster, P.N., Krischer, J., Tamura, R., Bello-Matricaria, L., Fink, A., McCaskill-Stevens, W., Guglin, M.

Get full text

A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma by Thomas, S., Aggarwal, R., Jahan, T., Ryan, C., Troung, T., Cripps, A.M., Raha, P., Thurn, K.T., Chen, S., Grabowsky, J.A., Park, J., Hwang, J., Daud, A., Munster, P.N.

“…Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin…”
Get full text

Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases by ZHENG, F. F, KUDUK, S. D, CHIOSIS, G, MÜNSTER, P. N, SEPP-LORENZINO, L, DANISHEFSKY, S. J, ROSEN, N

“…Geldanamycin (GM) is a natural antibiotic that binds Hsp90 and induces the degradation of receptor tyrosine kinases, steroid receptors, and Raf. It is a potent…”
Get full text

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer by Münster, P N, Buzdar, A, Dhingra, K, Enas, N, Ni, L, Major, M, Melemed, A, Seidman, A, Booser, D, Theriault, R, Norton, L, Hudis, C

“…We conducted this phase I trial to determine the safety and toxicity profile of LY353381.HCl-a novel, potent, third-generation selective estrogen receptor…”
Get full text

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors by Garon, E.B., Wong, D.J., Schneider, J.G., Aljumaily, R., Korn, W.M., Patel, M.R., Autio, K.A., Papadopoulos, K.P., Naing, A., Gabrail, N., Munster, P.N., Goldman, J., Hung, A., Oft, M., Leveque, J., Spigel, D.R.

Get full text

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells by MUNSTER, Pamela N, TROSO-SANDOVAL, Tiffany, ROSEN, Neal, RIFKIND, Richard, MARKS, Paul A, RICHON, Victoria M

“…Histone deacetylase (HDACs) regulate histone acetylation by catalyzing the removal of acetyl groups on the NH(2)-terminal lysine residues of the core…”
Get full text

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells by MÜNSTER, Pamela N, SRETHAPAKDI, Mary, MOASSER, Mark M, ROSEN, Neal

“…17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) is an ansamycin antibiotic that binds to a conserved pocket in Hsp90 and induces the degradation of proteins…”
Get full text

A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) by Kelley, R. K., Nimeiri, H. S., Vergo, M. T., Bergsland, E. K., Ko, A. H., Munster, P. N., Reinert, A., Mulcahy, M. F., Benson, A. B., Venook, A. P.

“…Abstract only…”
Get full text

Arzoxifene: the development and clinical outcome of an ideal SERM by Munster, Pamela N

“…Hormone-sensitive tumours are among the most common cancers in women. Specific inhibition of the estrogen receptor by selective estrogen receptor…”
Get more information

192PDRandomized trial of lisinopril or carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving trastuzumab by Munster, P N, Krischer, J, Tamura, R, Bello-Matricaria, L, Fink, A, McCaskill-Stevens, W, Guglin, M

Get full text

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer by Munster, P N, Norton, L

“…One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient…”
Get full text

1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors by Garon, E B, Wong, D J, Schneider, J G, Aljumaily, R, Korn, W M, Patel, M R, Autio, K A, Papadopoulos, K P, Naing, A, Gabrail, N, Munster, P N, Goldman, J, Hung, A, Oft, M, Leveque, J, Spigel, D R

Get full text

High-dose therapy for breast cancer by Hudis, C A, Münster, P N

“…In recent years, the most frequent indication for high-dose autologous stem-cell-supported chemotherapy in the United States has been breast cancer. This…”
Get more information